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EDITORIAL
Manufacturing of hybrid drug delivery systems by utilizing the fused filament 
fabrication (FFF) technology
Georgios K. Eleftheriadis a, Christos S. Katsiotis a, Natalja Geninab, Johan Boetkerb, Jukka Rantanenb 
and Dimitrios G. Fatourosa
aDepartment of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece; bDepartment of Pharmacy, University of Copenhagen, 
Copenhagen, Denmark
ABSTRACT
The potential of fused filament fabrication (FFF) for the administration of active pharmaceutical 
compounds is a recent approach to develop complex and custom-made drug delivery systems 
(DDSs). However, the FFF technology is characterized by certain limitations, which are associated with 
the nature of the process, i.e., the required mechanical properties of the feedstock, as well as the 
thermal stability of the incorporated polymers, excipients and active compounds. Thus, hybrid DDSs 
have been recently introduced, to overcome these boundaries. The concept of these systems is defined 
by the effective coupling of FFF with conventional manufacturing technologies, as a novel pathway to 
expand the available pool of raw materials and pharmaceutical applications of FFF.
ARTICLE HISTORY
Received 23 March 2020  
Accepted 27 May 2020  
KEYWORDS
3D printing; automated 
filling; biologics; 
electrospinning; hybrid 
systems; injection molding; 
inkjet printing; fused 
filament fabrication
1. Introduction
The potential of additive manufacturing, and especially the use 
of three-dimensional (3D) printing technologies for the devel-
opment of novel drug delivery systems (DDSs), has been pro-
ven over the past decade [1]. The fused filament fabrication 
(FFF) technique is the key technology when aiming for design-
ing complex DDSs with unique properties, e.g., various geome-
tries and multilayered structures providing tailored drug release 
profiles or site specificity [1–3]. A thermoplastic polymer-based 
filament is the feedstock in FFF. The filaments are either com-
mercially available or developed by the hot melt extrusion 
(HME) process; thus, the coupling of HME with FFF for on- 
demand fabrication of DDSs is a common approach [4]. The 
filament is gear-forced in the heating block of the printhead. 
This chamber is usually operated at elevated temperatures, 
above the glass transition, the melting or softening point of 
the polymer, to increase the mobility of the polymer chains. 
Subsequently, the melt flows through the nozzle of the print-
head and deposits onto the build platform, thereby solidifying 
at predetermined patterns, according to the digital design of 
a 3D object [5]. The FFF printing provides the ability to develop 
versatile and complex structures, and also the implementation 
of product design principles in a cost-effective and patient- 
centered fashion [6]. Nonetheless, the nature and process of 
this technique present limitations to the active pharmaceutical 
ingredients (APIs) and excipients that can be used. Thermal 
degradation, a limited choice of printable (thermoplastic) mate-
rials suitable for oral uptake, and unique physical characteristics 
of the feedstock are just some evident shortcomings observed 
with FFF. Moreover, the scale-up of the printing process, along 
with the mass production of these products, has yet to be 
achieved. To overcome these boundaries, a few hybrid DDSs 
have been recently introduced (Table 1) [7]. The hybrid systems 
comprise a primary FFF-printed component, complemented by 
additional elements. The latter are principally produced via 
conventional or equally novel methods, e.g., compression, elec-
trospinning, injection molding, and inkjet printing. This hybrid 
proof-of-concept approach aims to resolve the shortcomings of 
the FFF process, resulting in the fabrication of DDSs with 
enhanced functional properties.
2. Hybrid drug delivery systems
2.1. Filled formulations
Container-like shapes can be effectively manufactured in 
a tailor-made approach via FFF; an array of filling formulations 
has been suggested to occupy the interior of the printed 
object. These formulations are produced by other techniques, 
and the filling procedure can be realized through (a) manual 
filling or (b) automated filling.
The produced hybrid DDSs incorporate the advantages of 
both manufacturing facets. For instance, the manual-filling 
approach provides the potential to incorporate a thermolabile 
API in the DDS, avoiding the unnecessary thermal stress to the 
sensitive API throughout the HME and FFF processing of the 
primary material. At the same time, this approach provides the 
possibility to adjust and tightly regulate the targeted delivery 
and the release mechanism of the API. Floating systems have 
been developed by combining FFF and tablet compression, 
exhibiting controlled drug release [8–10]. Furthermore, 
a floating device was designed and printed by FFF, aiming to 
host a commercially available drug-loaded capsule [11]. 
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Multicompartmental devices, loaded with SNEDDS [12], drug- 
loaded hot melt extrudates [13] or bulk APIs [14,15], and suppo-
sitory dosage forms [16], were also fabricated. Moreover, regular 
tablet and capsule shapes have been investigated as potential 
carriers that provide the targeted drug delivery of alginate beads 
[17] and hydrogels [18]. The possibility of adopting innovative 
designs in these multicompartmental devices allows achieving 
completely new types of drug release behavior (Figure 1) [19].
According to additional studies, the one-step fabrication 
and filling of the object was reported. The development of 
hollow formulations via both manual and automated filling of 
capsules with solid granules and a liquid formulation, respec-
tively, has been investigated, including the consideration of an 
in vitro/in vivo relationship [20]. Such an approach can unite 
the advantages of the FFF technique with an additional time- 
saving merit, compared to manual filling. Ordinarily, the auto-
mated filling process is realized upon modifying a dual- 
extruder 3D printer, by replacing a printhead with a syringe 
[20,21]. Recently, a modular 3D printer, previously used only 
for tissue applications, provided the ability of both FFF print-
ing and injection volume filling [22]; this device facilitated the 
development of capsules with unique drug release profiles of 
solutions and suspensions.
2.2. FFF/electrospinning
One of the earliest adoptions of 3D printing in combinatorial 
systems for drug delivery was the coupling of FFF with 
electrospinning (ES) to produce drug loaded scaffolds [23]. 
The ES process generates fibers of various diameters, inex-
pensively, with their most crucial advantage being that they 
can mimic the extracellular matrix. In turn, FFF is utilized 
both for its rapid structure prototyping capabilities and the 
mechanical properties of the objects. Thus, a drug-loaded 
electrospun graft was shielded with a 3D-printed outer layer 
to improve the mechanical properties and structural integ-
rity of the scaffold. More recently, the reverse approach was 
implemented by adjusting the pore size of 3D-printed scaf-
folds to address the needle-and-thread fixing of nasal carti-
lage implants, and subsequently, overlaying them with an 
electrospun drug-containing hydrogel to improve the cell 
adhesion and proliferation properties of the scaffold [24].
2.3. Other systems
Finally, FFF has been coupled with other processes and mate-
rials to produce layered formulations, due to the high custo-
mizability and rapid prototyping capability of this technique. 
In an attempt to overcome the limitation of FFF, regarding the 
possibility for mass production, Fuenmayor and his coworkers 
have studied a hybrid system, where injection molding (IM) 
and FFF were employed to develop bilayer dual drug- 
containing tablets [25]. The small FFF-printed part of the tablet 
provided a customizable and personalized dosage of the first 
API. This 3D-printed part was subsequently inserted in the 
mold, where the larger part of the tablet, containing a non- 
Table 1. Hybrid drug delivery systems that incorporate the FFF technology (ABS, acrylonitrile butadiene styrene; EC, ethyl cellulose; HPC, hydroxypropyl cellulose; 
HPMC, hydroxypropyl methylcellulose; HPMCAS, hydroxypropyl methylcellulose acetate succinate; PCL, poly – ε – caprolactone; PEO, polyethylene oxide; PLA, 
polylactic acid; PLLA, Poly L-lactic acid; PVA, poly(vinyl alcohol)).
Category Filament type/origin Active ingredient Aim Ref.
Manual Filling PLA commercial riboflavin A gastric floating device with ease of manufacturing [8]
PVA, ABS commercial metronidazole A gastric floating device with constant drug release [9]
HPC, EC in-lab theophylline A gastric floating device with desirable lag time for pulsatile 
release
[10]
PVA commercial amoxicillin A gastric floating device to provide prolonged drug release 
in the stomach
[11]
PVA, PLA commercial carbamazepine, halofantrine, 
saquinavir
Compartmental dosage forms with multiple active 
ingredients
[12]
PVA, PLA commercial isoniazid, rifampicin B An anti-tuberculosis dual-compartmental device to 
modulate drug release
[13]
PLA, PVA commercial, HPMC, 
HPMCAS in-lab
acetaminophen and dyes Separate inner compartments forming a capsular device [14]
PVA commercial dronedarone hydrochloride, 
ascorbic acid
Separate inner compartments providing predictable drug 
release profiles
[15]
PVA commercial progesterone 3D printed suppository molds for filling with different 
suppository formulations
[16]
PLA commercial Eudragit L100-55 
Eudragit S100
5-Fluorouracil pH responsive for colonic targeting with controlled release [17]
HPMC phthalate in-lab macromolecular dye Gastroresistance, sustained release [18]
PVA commercial lamivoudine, unknown 
proprietary Merck API
Flexibility in the form of the drug carrier [20]
Automated/ 
Manual Filling
PVA commercial lamivoudine, unknown 
proprietary Merck API
Automation, one-step process printing and filling. [20]
Automated Filling Eudragit EPO, Eudragid RL in-lab dipyridamole, theophyline Instantaneous printing and filling of liquid capsules [21]





PCL (FFF apparatus) heparin Tubular scaffold reinforced with an outer layer [23]
PLLA commercial osteocalcin, hydroxyapatite, 
type I collagen
Improvement of cell adhesion and proliferation [24]
Other systems PCL, PEO, Kollidon in-lab hydrochlorothi–azide, lovastatin Mass-customization, multi-drug loading and diverse release 
profiles
[25]
HPC in-lab, PLA, PVA commercial paracetamol Measures to assure authenticity and tracking [26]
PVA, EC in-lab diclofenac sodium Utilization of commercial edible sheet in 3D printing as 
backing layer
[27]
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patient-specific dose of the second API, was produced. Thus, 
the mass production capabilities of IM were exploited and 
combined with the patient-centric orientation of FFF. In 
a recent study, the coupling of FFF with inkjet printing was 
explored to prepare quick response (QR) codes and data 
matrices onto 3D printed tablets, as anti-counterfeit measures 
[26]. An alternative approach, compared to the conventional 
methodologies in the development of multilayered buccal 
films, was recently reported. Drug loaded buccal films were 
fabricated via FFF onto commercial wafer paper, commonly 
used as a substrate for inkjet printing [27]. The wafer acted as 
the backing layer and imparted unidirectional release properties 
to the formulations, by effectively inhibiting the extensive diffu-
sion of the API toward the oral-cavity-simulating environment.
3. Conclusion
The emergence of 3D printing in pharmaceutics is evident by the 
increasing number of publications over the last decade and the 
establishment of startup companies moving toward this direc-
tion, due to the multifaceted advantages it offers. The recent 
coupling of 3D printing with several other techniques and 
approaches was found both successful and promising, regarding 
the development of hybrid DDSs, by uniting their respective 
advantages and avoiding limitations of each technique.
4. Expert opinion
The recent expiration of patents related to additive manufac-
turing devices was a key to the successful introduction of the 
3D printing technology in the list of cutting-edge formulation 
processes [28]. The commercial release of the first 3D-printed 
tablet (Spritam®, Aprecia Pharmaceuticals), together with the 
first reported application of FFF in pharmaceutical technology 
[29], stimulated the academic sector globally. This develop-
ment was further motivating the emergence of novel formula-
tion approaches for drug delivery by using the FFF 
technology. Since then, a growing number of printable mate-
rials has been reported during the development of FFF-printed 
DDSs; however, it should be noted that this number is mod-
erate compared to the available thermoplastic polymers, exci-
pients, and APIs used in the development of pharmaceutical 
products via standard technologies (e.g., granulation, tablet-
ing, pelletization, coating). A key aspect in this work is to build 
the knowledge base for finding out the unique possibilities of 
FFF that the conventional drug manufacturing solutions lack 
[30]. Beyond the common drawbacks of additive manufactur-
ing (object anisotropy, mass production issues), the bound-
aries of FFF are defined by the intimate nature of the process 
[6]. The required mechanical strength and physical dimensions 
of the filaments are essential to facilitate the smooth and 
continuous feeding of the filament to the printhead, which 
would result in objects with excellent accuracy and repeat-
ability. Another critical attribute that should be considered is 
the high-thermal processing of the feedstock throughout the 
build cycle, raising the burden of thermal degradation and 
rendering the FFF printing of thermosensitive constituents 
arbitrary. At this point, hybrid DDSs are providing excellent 
potential to tackle the current limitations of FFF. With global 
digitalization, other drug manufacturing solutions, e.g., inkjet 
printing, can be utilized ad hoc to FFF and used to generate 
drug-containing data matrices that would make the supply 
chain of pharmaceuticals transparent and protected against 
counterfeiting [31,32].
The recent FDA- and industry-driven trends are moving 
toward addressing the current clinical needs via the existing 
Figure 1. Illustration of the potential of 3D printing for engineering drug release. The rows are representative examples of (from top to bottom): different tablet 
geometries (tablet length is denoted as L), their respective plots of normalized tablet width (w), and the experimental/theoretical data of drug release (blue/red 
dotted lines) corresponding to the different tablet shapes. Reprinted with permission from reference [19].
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additive manufacturing techniques [33]. On the other hand, 
there is a constantly growing number of new biologics 
approved by the FDA, accounting for sixty-nine new biologics 
approvals in the past few years (2014–2019) and 21% of the 
total approvals of therapeutics in 2019 [34–36], which are 
expected to dominate the global pharmaceutical market [37]. 
Similarly, several life-saving antiviral treatments are based on 
multi-drug administration, including treatment of, e.g., HIV 
and hepatitis C. Accordingly, efforts in this era to combat the 
pandemic COVID-19 are currently (end of March 2020) cen-
tered around multi-drug solutions [38]. Additive manufactur-
ing might have a key role to personalize the production for 
both clinical trials as well as final commercial scale. As thermal 
degradation at moderate temperatures represents a major 
issue for most biologics and even small molecules, the devel-
opment of hybrid DDSs for the effective delivery of these 
molecules can be a logical solution. Compartmentalized 
hybrid DDSs allow for personalization of not only the dose 
of different compounds in the same dosage unit, but also 
customization of the release behavior for each incorporated 
drug (Figure 2).
Overall, hybrid DDSs are thoroughly expanding the capabil-
ities of FFF together with other traditional manufacturing 
processes to a considerable extent of applications in the phar-
maceutical and medical fields. Conceptual treatments that are 
often described in the literature, regarding the incorporation 
of model drugs, might be eventually translated to clinical 
practice via hybrid DDSs. Considering the academic effort 
that has been done in this field during the last years, and 
the exceptionally broad spectrum of available manufacturing 
technologies, more combinatorial approaches are expected to 
emerge in the immediate future. These approaches are 
believed to provide smart solutions to the current clinical 
needs from the aspect of personalized treatments.
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